Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1974 1
1979 2
1983 1
1984 1
1987 3
1988 2
1995 1
1996 1
1997 2
1998 1
1999 1
2000 2
2002 1
2003 2
2004 2
2005 1
2006 1
2007 4
2008 8
2009 8
2010 10
2011 9
2012 4
2013 7
2014 9
2015 6
2016 8
2017 6
2018 5
2019 9
2020 5
2021 10
2022 10
2023 13
2024 8
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, Klion AD; International Eosinophil Society Clinical Research Interest Group. Khoury P, et al. J Leukoc Biol. 2024 Jul 25;116(2):307-320. doi: 10.1093/jleuko/qiae051. J Leukoc Biol. 2024. PMID: 38457125 Free PMC article. Review.
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M; POLA Network. Kacimi SEO, et al. Among authors: carpentier c. J Clin Oncol. 2025 Jan 20;43(3):329-338. doi: 10.1200/JCO.24.00049. Epub 2024 Oct 2. J Clin Oncol. 2025. PMID: 39356975
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network. Picca A, et al. Among authors: carpentier c. Eur J Cancer. 2024 May;202:114034. doi: 10.1016/j.ejca.2024.114034. Epub 2024 Mar 22. Eur J Cancer. 2024. PMID: 38537315 Free article. Clinical Trial.
Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.
Chaillet N, Mâsse B, Grobman WA, Shorten A, Gauthier R, Rozenberg P, Dugas M, Pasquier JC, Audibert F, Abenhaim HA, Demers S, Piedboeuf B, Fraser WD, Gagnon R, Gagné GP, Francoeur D, Girard I, Duperron L, Bédard MJ, Johri M, Dubé E, Blouin S, Ducruet T, Girard M, Bujold E; PRISMA Trial research group. Chaillet N, et al. Lancet. 2024 Jan 6;403(10421):44-54. doi: 10.1016/S0140-6736(23)01855-X. Epub 2023 Dec 11. Lancet. 2024. PMID: 38096892 Clinical Trial.
153 results